| The best tirzepatide alternatives for weight loss include injectable semaglutide, the oral semaglutide tablet for weight management (now available in US pharmacies), phentermine/topiramate (Qsymia), bupropion/naltrexone (Contrave), metformin, compounded GLP-1 medications, and medically supervised weight loss programs. Each option works through different mechanisms, with GLP-1 receptor agonists like semaglutide producing the strongest results closest to tirzepatide. |
Tirzepatide has changed what is possible in medical weight loss, with average weight loss of up to about 21% of body weight at 72 weeks in the SURMOUNT-1 trial. But not everyone can access it. Insurance denials, supply issues, medication costs, and certain health conditions, including personal or family history of thyroid cancer, pancreatitis, or severe GI conditions, may put tirzepatide out of reach.
Fortunately, there are several proven options. For Texas patients, InjectCo clinics across the DFW metroplex, Plano, Fort Worth, Austin, The Woodlands, and Colleyville offer physician-supervised GLP-1 programs including semaglutide, tirzepatide, and compounded alternatives.
Book a free virtual consultation to find the right fit for your goals.
| 1. Injectable Semaglutide | Closest GLP-1 alternative to tirzepatide | |
| Mechanism | GLP-1 receptor agonist |
| FDA Status | Approved (one brand-name injection for chronic weight management, another for type 2 diabetes) |
| Average weight loss: about 15% of body weight at 68 weeks in the STEP 1 trialForm: once-weekly subcutaneous injectionHow it works: GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and improves blood sugar regulationBest for: adults with obesity or overweight seeking a well-studied, once-weekly GLP-1 treatment with strong clinical trial dataAvailable at InjectCo: yes, with physician-guided dosing and flexible titration support | |
| 2. Oral Semaglutide Tablet | Approved December 2025 as an oral GLP-1 for weight management | |
| Mechanism | GLP-1 receptor agonist (oral) |
| FDA Status | Approved December 22, 2025, now widely available |
| Why it matters | No other oral GLP-1 with this level of weight loss data existed before this approval |
| Average weight loss: about 14% to 17% at 64 weeks in the OASIS 4 Phase 3 trialForm: once-daily oral tablet, no injections, no refrigeration requiredHow it works: the same semaglutide molecule as the injectable version, taken by mouth once a day, with the dose raised step by step by your prescriberBest for: patients who prefer pills over injections, those with needle anxiety, or anyone who could not tolerate injectable GLP-1sAvailability: by prescription at major US pharmacies since January 5, 2026Important note: take 30 minutes before eating with a small amount of water; do not crush or chew | |
| 3. Retatrutide (Triple Agonist GLP-1 + GIP + Glucagon) | The next-generation drug to watch | |
| Mechanism | Triple hormone receptor agonist: GLP-1 + GIP + glucagon |
| FDA Status | NOT FDA-APPROVED. Still investigational in the Phase 3 TRIUMPH program. |
| Why include it here?In the Phase 3 TRIUMPH-1 trial, adults with obesity lost about 25% of body weight on average at 80 weeks (about 28% in those who stayed on treatment).It targets three hormone pathways vs. tirzepatide’s two (GLP-1 + GIP).Retatrutide is not FDA-approved and is not available by prescription or at pharmacies. Any product sold as retatrutide outside a clinical trial is not an approved medicine. | |
| 4. Phentermine / Topiramate (Qsymia) | Fastest oral option for short-term weight reduction | |
| Mechanism | CNS stimulation + satiety enhancement |
| FDA Status | Approved for chronic weight management |
| Caution | Not for long-term use in most patients; cardiovascular contraindications |
| Average weight loss: about 8% to 10% of body weight at 56 weeks in the CONQUER trialForm: once-daily oral capsule (appetite suppressant + metabolism enhancer)How it works: phentermine stimulates the central nervous system to reduce appetite; topiramate increases satiety and reduces calorie intakeBest for: adults needing faster near-term weight reduction who prefer oral medication and do not have cardiovascular diseaseConsiderations: not recommended for patients with heart disease, history of stroke, hyperthyroidism, or glaucoma; requires pregnancy prevention in women of childbearing ageNote: this is not a GLP-1 medication and does not carry the same long-term metabolic benefits as semaglutide or tirzepatide | |
| 5. Bupropion / Naltrexone (Contrave) | For patients with craving-driven or emotional eating patterns | |
| Mechanism | Targets brain reward and appetite centers |
| FDA Status | Approved for chronic weight management |
| Key difference | Addresses behavioral drivers of overeating, not just metabolic factors |
| Average weight loss: about 6% of body weight at 56 weeks in the COR-I trialForm: oral tablet taken twice dailyHow it works: bupropion acts on dopamine and norepinephrine pathways; naltrexone blocks opioid receptors involved in food reward and craving cyclesBest for: patients whose weight gain is driven by emotional eating, cravings, or addictive food behaviors rather than purely metabolic factorsConsiderations: may increase blood pressure; not for patients with seizure disorders, those using opioid medications, or patients with active bulimia/anorexia | |
| 6. Metformin (off-label for weight loss) | Budget-friendly metabolic support for patients with elevated blood sugar | |
| Mechanism | Insulin sensitizer; reduces hepatic glucose output |
| FDA Status | Approved for T2D; off-label for weight loss |
| Best pairing | Often combined with GLP-1 therapy or lifestyle programs for additive benefit |
| Average weight loss: modest, but meaningful for some patientsForm: oral tablet taken once or twice daily with mealsHow it works: improves insulin sensitivity, reduces hepatic glucose production, and may modestly suppress appetiteBest for: patients with metabolic syndrome, prediabetes, or type 2 diabetes who need affordable, well-tolerated weight supportConsiderations: prescribed off-label for weight loss; not a substitute for GLP-1 therapy in patients with significant obesity. Most effective as part of a broader program. | |
| 7. Medically Supervised Weight Loss Programs | The most sustainable long-term alternative for patients who need personalized care | |
| Approach | Multi-modal: medication + lifestyle + behavioral support |
| Supervision | Physician or NP-guided with regular check-ins |
| Availability | InjectCo: 9 Texas locations + virtual consultations statewide |
| What is included: physician or NP-guided program combining prescription medication, nutrition counseling, behavioral support, and regular monitoringAverage weight loss: variable, but higher adherence and sustainability than self-managed dietingBest for: anyone seeking a supervised, individualized approach, especially patients who have tried medications alone without long-term resultsAt InjectCo: our BriteBody medical weight loss program pairs GLP-1 medications with coaching and check-ins across 9 Texas locations including Fort Worth, Plano, Dallas, Austin, The Woodlands, Colleyville, Argyle, Cleburne, and WaxahachieBook a free 15-minute virtual consultation at injectco.com to discuss which medications and programs fit your goals | |
Use this table to compare your options side by side before your consultation.
| Alternative | Type | Avg. Weight Loss | Form | FDA Status | Best For |
| Semaglutide (injectable) | GLP-1 RA | About 15% (STEP 1) | Weekly injection | Approved | Proven weekly GLP-1 for obesity |
| Oral semaglutide tablet | GLP-1 RA (oral) | About 14% to 17% (OASIS 4) | Daily pill | Approved Dec 2025 | No-needle GLP-1 option |
| Liraglutide | GLP-1 RA | About 8% (SCALE) | Daily injection | Approved | Daily dosing preference |
| Phentermine/Topiramate | Appetite suppressant | About 8% to 10% (CONQUER) | Daily pill | Approved | Short-term, oral-only patients |
| Bupropion/Naltrexone | Craving control | About 6% (COR-I) | Daily pill | Approved | Emotional/craving-driven eating |
| Metformin (off-label) | Insulin sensitizer | Modest | Daily pill | Off-label | Metabolic syndrome, budget patients |
| Retatrutide (GIP+GLP-1+glucagon) | Triple agonist | About 25% (TRIUMPH-1) | Weekly injection | NOT yet approved – Phase 3 | Future: patients needing max loss |
| Compounded GLP-1s | Custom peptide | Variable | Injectable | Not FDA-approved | Access/cost barriers to brand-name |
| Medical Weight Loss Programs | Multi-modal | Variable / sustained | Customized | N/A | Long-term, physician-supervised |
Cost is one of the biggest factors patients weigh when choosing a tirzepatide alternative. Here is what InjectCo’s program costs for Texas patients:
| Medication | Monthly Cost (self-pay) | With Insurance | Notes |
| Compounded semaglutide (InjectCo) | $425/mo, or $1,800 for a 6 to 8 month program | N/A | Physician-supervised program |
| Compounded tirzepatide (InjectCo) | $425/mo, or $1,800 for a 6 to 8 month program | N/A | Physician-supervised program |
InjectCo pricing note: InjectCo’s medical weight loss program is $425 a month or $1,800 for a 6 to 8 month program. Book a consultation to see whether it suits you. We also accept CareCredit and Cherry financing for eligible patients.
The oral semaglutide tablet for weight management launched in US pharmacies on January 5, 2026, marking the first time a GLP-1 receptor agonist for obesity has been available in pill form. It is available by prescription at US pharmacies.
Key facts for patients:
For Texas patients who want to explore whether the oral semaglutide tablet or another GLP-1 option fits their lifestyle, InjectCo providers at our Fort Worth, Plano, Dallas, Austin, Colleyville, The Woodlands, Argyle, Cleburne, and Waxahachie locations can help you compare options and build a supervised plan.
There is no single best alternative for everyone. The right option depends on:
Always work with a qualified medical provider before starting or switching weight loss medications. At InjectCo, every patient starts with a consultation where our team reviews your health history and builds a plan that fits your goals, medical needs, and budget.
At InjectCo, we do not take a one-size-fits-all approach to weight loss. Our providers review your full health history, discuss your previous experiences with medications, and match you with the best available option, whether that is injectable semaglutide, compounded GLP-1 medications, our BriteBody program, or another treatment entirely.
We serve patients across Texas at nine locations:
Book your free 15-minute virtual consultation and let our team find the right plan for you.
Injectable semaglutide is the closest alternative. Both are GLP-1 receptor agonists, both are given weekly, and semaglutide has the strongest clinical data of any currently approved single-pathway alternative. Tirzepatide adds a second hormone pathway (GIP) which accounts for its slightly greater average weight loss, and in the STEP 1 trial semaglutide produced about 15% average weight loss at 68 weeks.
No. There is no FDA-approved oral tirzepatide. However, a brand-name oral semaglutide tablet launched in January 2026 as an FDA-approved oral GLP-1 for chronic weight management. It is available now at major US pharmacies.
Retatrutide is a next-generation triple agonist developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. In the Phase 3 TRIUMPH-1 trial, adults with obesity lost about 25% of body weight on average at 80 weeks. However, retatrutide is not FDA-approved and remains investigational. Any product sold as retatrutide outside a clinical trial is not an approved medicine.
Most are. Brand-name injectable semaglutide, the brand-name oral semaglutide tablet, liraglutide, phentermine/topiramate (Qsymia), and bupropion/naltrexone (Contrave) are all FDA-approved for obesity or chronic weight management. Metformin is FDA-approved for type 2 diabetes and used off-label for weight support. Compounded GLP-1 medications are not FDA-approved but can be legally prescribed by licensed providers. Retatrutide remains investigational.
Brand-name tirzepatide, whether prescribed for diabetes or for weight loss, activates both the GLP-1 and GIP receptors. Most alternatives, including semaglutide, only activate the GLP-1 receptor, which is one reason their average weight loss is somewhat lower: about 15% at 68 weeks for semaglutide in STEP 1, versus up to about 21% at 72 weeks for tirzepatide in SURMOUNT-1. The oral semaglutide tablet delivers similar GLP-1 receptor activity in pill form, with about 14% to 17% average weight loss in the OASIS 4 trial.
InjectCo offers compounded semaglutide, compounded tirzepatide, and our BriteBody medical weight loss program at nine Texas locations. We also connect patients with brand-name GLP-1 options and provide clinical guidance on oral alternatives. Book a free consultation to discuss what fits your goals.
It depends on the medication and on you. Average results in clinical trials: injectable semaglutide about 15% at 68 weeks (STEP 1), oral semaglutide about 14% at 64 weeks (OASIS 4), phentermine/topiramate about 8% to 10% at 56 weeks (CONQUER), bupropion/naltrexone about 6% at 56 weeks (COR-I), and modest loss with metformin. Retatrutide, which is not FDA-approved, averaged about 25% at 80 weeks (TRIUMPH-1). Results depend on adherence, dosage, medical history, and lifestyle factors.
InjectCo has nine Texas locations and offers free virtual consultations for patients statewide. Our providers specialize in GLP-1 weight loss programs and can help you find the right medication or program whether you are new to treatment or looking to switch from a medication that stopped working for you.
Medical Disclaimer: Medical weight loss treatment is prescribed only after a clinical consultation and is not appropriate for everyone. Whether you are a candidate is decided by a licensed provider, not by any tool or information on this page. Results vary between individuals and depend on adherence, diet, and activity.
Dr. Allen earned his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine and completed his emergency medicine residency with Texas A&M. Treatments at InjectCo are provided under the medical direction of Dr. Josh Allen, D.O., Medical Director, who oversees InjectCo’s treatment protocols and safety standards across all nine Texas locations.
days day
hours hour
minutes minute
seconds second
